◆ NeutralSION
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
GlobeNewswire Inc.·
The Law Offices of Frank R. Cruz is investigating Sionna Therapeutics for potential federal securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, causing significant investor losses.
Read Full Article at GlobeNewswire Inc. →